Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 8/20 | 0.69 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | CDC42 | P60953 | 1/20 | 0.69 |
| ▸ | RAC1 | P63000 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.69 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6740891 | 0.85 | UTS2R (0.51) | AKR1C3AKR1C2PTGS1PTGS2TSHR | |
| SCHEMBL17295985 | 0.84 | LDHA (0.52) | AKR1C3AKR1C2PTGS1PTGS2TSHR | |
| SCHEMBL3829660 | 0.84 | LDHA (0.52) | AKR1C3AKR1C2PTGS1PTGS2TSHR | |
| SCHEMBL17295989 | 0.84 | LDHA (0.52) | AKR1C3AKR1C2PTGS1PTGS2TSHR | |
| SCHEMBL8333146 | 0.83 | AKR1C3 (0.73) | AKR1C3AKR1C2PTGS1PTGS2TSHR | |
| SCHEMBL18890289 | 0.81 | L3MBTL1 (0.56) | PTGS1LMNATDP1L3MBTL1 | |
| Naproxen SCHEMBL42434 | 0.81 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2TSHR | |
| Naproxen SCHEMBL215236 | 0.81 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2TSHR | |
| SCHEMBL21326187 | 0.81 | L3MBTL1 (0.56) | PTGS1LMNATDP1L3MBTL1 | |
| Naproxen SCHEMBL616149 | 0.81 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| US-4207241-A | ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS AND ANTIPRURITIC AGENTS | SYNTEX CORPORATION (US) | 1980-06-10 | — | — | US | disclosed |
| US-4097674-A | ANTIINFLAMMATORY, ANTIPYRETIC, ANTIPRURITIC AGENTS, ANALGESICS | SYNTEX CORPORATION (US) | 1978-06-27 | — | — | US | disclosed |
| US-4051233-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC, ANTIPRURITIC | SYNTEX CORPORATION (US) | 1977-09-27 | — | — | US | disclosed |
| US-4001301-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS, ANTI-PRURITIC | SYNTEX CORPORATION (PM) | 1977-01-04 | — | — | US | disclosed |
| US-3998966-A | Anti-inflammatory, analgesic, anti-pyretic and anti-pruritic 6-substituted 2-naphthyl acetic acid derivative-containing compositions and methods of use thereof | SYNTEX CORPORATION (PM) | 1976-12-21 | — | — | US | disclosed |
| US-3980699-A | ANTIINFLAMMATORY, ANALGESICS, ANTIPYRETIC, ANTIPRURITIC | SYNTEX CORPORATION (PM) | 1976-09-14 | — | — | US | disclosed |
| US-3978116-A | ANALGESIC, ANTIPYRETIC | SYNTEX CORPORATION (PM) | 1976-08-31 | — | — | US | disclosed |
| US-3978124-A | ANALGESIC, ANTIPYRETIC | SYNTEX CORPORATION (PM) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | AKR1C3 2566/4885AKR1C2 3493/4885PTGS1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.